SNIPR targets the microbiome

How SNIPR's CRISPR microbiome IP drew Lundbeckfonden Emerge, LSP for $50M A round

SNIPR's strong IP position in prokaryotic CRISPR drew investors to a $50 million venture round led by Lundbeckfonden Emerge and LSP, the biggest series A yet for a CRISPR antibiotics and autoimmune company.

Lundbeckfonden Emerge's Christian Elling told BioCentury the early stage investment firm seeded SNIPR Biome

Read the full 463 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE